AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05097586 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Sham stimulation in which the current turns off after 30 seconds in a slow ramp down that mirrors sensory adaptation in ongoing stimulation, delivered in 15 sessions lasting 30 minutes each over 3 weeks
Study NCT05061303 — intervention group
Intervention type: OTHER
Intervention: Assessment of the drug concentration in the blood
Description: The material in the study will be blood, in which tacrolimus concentrations will be measured at the following time points: 0, 2hours, 6hours, 12hours after drug administration, without taking omeprazole/famotidine and then the next day after taking the protective drug in same time points, without 12hours. Sequentially routinely in the so-called point T0 before taking the drug (12 hours after the last dose) during follow-up visits at the Transplant Outpatient Clinic.
Study NCT06333873 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: patient-reported outcome
Description: Performance of real-life tests and tasks
Study NCT05136963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: 5 milliliter of iohexol will be administrated.
Study NCT05136963 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pharmacokinetics
Description: 10 blood samples of 5 milliliter will be performed. sampling time ater administration of Iohexol: 00h30, 1h00, 1h30, 02h00, 03h00, 04h00, 05h00, 06h00, 09h00 and 12h00
Study NCT05366283 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Sargramostim is a glycosylated, yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor.
Study NCT06326242 — intervention group
Intervention type: OTHER
Intervention: Solid Tumor
Description: The study focuses on defining the problem of geographical accessibility of patients to the Phase 1 facility of the European Institute of Oncology, based on anonymized data extraction from the enrolled patient database, to evaluate national territorial disparities in access to innovative experimental therapies, in relation to various socioeconomic determinants. Finally, relevant information on psychological factors for participation in clinical trials will also be collected.
Study NCT04878133 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OCT - optical coherence tomography
Description: The principle by which OCT works is similar to ultrasound, although light waves close to infrared are used instead of ultrasounds.~In practice, the light waves, emitted into the vessel through a special catheter positioned in the coronary artery, meet the surrounding structures and are partly absorbed and partly reflected by them. The reflected waves are picked up by a sensor positioned on the catheter and analyzed through software that produces images visible live on a special console.
Study NCT05769660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEY1107
Description: Administer twice daily, PO, 4-week continuous dose.
Study NCT05769660 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administer once daily, PO, 5-day continuous dose, followed by 23-day rest period.
Study NCT05087615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: This groups only received metoclopramide 0.2 mg/kg IV Bid as antiemetic in the postoperative period.
Study NCT05087615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: This groups only received ondansetron 8 mg IV Bid as antiemetic in the postoperative period.
Study NCT05087615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide and Ondanteron
Description: This groups received both metoclopramide 0.2 mg IV Bid and ondansetron 8 mg IV/Bid as antiemetics in the postoperative period.
Study NCT05087615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: This groups only received granisetron 2 mg IV Bid as antiemetic in the postoperative period.
Study NCT05464433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with Liposomal mitoxantrone hydrochloride
Description: Drug: liposomal mitoxantrone hydrochloride, tislelizumab Drug: Liposomal mitoxantrone hydrochloride (16 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: tislelizumab(200 mg) will be taken orally on day 1 of each 28-day cycle.
Study NCT05464433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance of tislelizumab
Description: Drug: tislelizumab(200 mg) will be taken orally on day 1 of each 21-day cycle
Study NCT05234580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA9159 nasal spray solution, 10 μg once daily for 14 days
Description: PA9159 of 10 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
Study NCT05234580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA9159 nasal spray solution, 20 μg once daily for 14 days
Description: PA9159 of 20 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
Study NCT05234580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA9159 nasal spray solution, 40 μg once daily for 14 days
Description: PA9159 of 40 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
Study NCT05234580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray solution without PA9159, once daily for 14 days
Description: Placebo nasal spray solution is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
Study NCT04886934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CS1 System
Description: Placement of CS1, a temporary bipolar myocardial electrode (TME) with an integrated motion sensor (accelerometer), on the left ventricle and externalization of the associated leads through the chest wall during open-heart surgery. CS1 will remain in place for up to 7 days after surgery and closure of the chest wall.
Study NCT05197803 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aid model
Description: Amplification
Study NCT05495204 — intervention group
Intervention type: DRUG
Intervention: Ibalizumab
Description: Participation in clinical trials vs. routine care in OPERA
Study NCT05873348 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation (FMT) is the use of functional microorganisms in the feces of healthy people to form capsules and orally administer them to the intestinal tract of patients to reconstruct the intestinal flora of patients, so as to achieve the purpose of treating intestinal and exenteric diseases.
Study NCT04390087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Upper-body rowing performed while participants are sitting in their own wheelchair.
Study NCT04723576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress First Aid
Description: Stress First Aid (SFA) is an evidence-based intervention to mitigate the psychosocial impact of COVID-19 on Health Care Workers (HCWs). SFA was initially developed for the United States Navy and Marine Corps as a framework of actions for peer support delivered by individuals without mental health training. SFA is designed to teach simple, supportive actions that can be seamlessly integrated into work environments. SFA training focuses on five essential principles: cover (restore and support a sense of safety), calm (encourage simple strategies such as breathing), connect (engage in and promote social support), competence (improve ability to address crucial needs and concerns), and confidence (increase hope and limit self-doubt and guilt). In this study, we are adapting the SFA model to include HCW-specific examples of SFA actions and case scenarios specific to the COVID-19 pandemic and will implement SFA using a train-the trainer model.
Study NCT05042427 — intervention group
Intervention type: OTHER
Intervention: Pregnancy Weight Management Health Literacy Questionnaire
Description: Give questionnaires to check the weight management health literacy level of primigravida women.
Study NCT05431257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Standard azacytidine treatment (AZA; D1-D7, 75mg/m2 qd) in combination with a short duration of low-dose venetoclax treatment (LD-VEN; D1-D14 before CR and D1-D7 after CR, 400mg qd) per 28 days cycle for elderly/unfit (arm 1) and relapsed/refractory (arm 2) patients with acute myeloid leukemia.
Study NCT05410548 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard-of-Care
Description: Participants with a major unilateral transfemoral or transtibial amputation will undergo a standardized medical history and medication review, complete questionnaires evaluating prosthesis use, comfort, and mobility, receive a clinical examination of height, weight and limb circumference, and complete three performance-based mobility outcome measures.
Study NCT05410548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard-of-Care
Description: Participants with a major unilateral transfemoral or transtibial amputation will undergo a standardized medical history and medication review, complete questionnaires evaluating prosthesis use, comfort, and mobility, receive a clinical examination of height, weight and limb circumference, and complete three performance-based mobility outcome measures.
Study NCT05410548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Screening
Description: Participants will complete the following self-report questionnaires: (a) the Patient Health Questionnaire-9 item, which may suggest major depression and/or suicidal ideation; and (b) the STarT Back Screening Tool, a 6-item tool used to screen for greater than low-risk for persistent, bothersome and disabling low back pain. Prosthetists will perform palpation of the contralateral dorsalis pedis and posterior tibial pulses and note presence or absence, as an indicator of peripheral arterial disease. Prosthetists will evaluate protective sensation of the contralateral foot through Semmes-Weinstein monofilament assessment of the great toe, the 1st and 3rd metatarsal heads. The prosthetist will record the results in a letter that is sent to the patient's primary care provider, and provide a copy of the letter to the patient after discussing the results for each of the screens.
Study NCT05513014 — intervention group
Intervention type: DRUG
Intervention: Secukinumab
Description: Patients with Psoriasis who initiated Secukinumab
Study NCT05765903 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: * Diagnosis education.~* Follow-appointment scheduling assistance.~* Offer resources in the community.~* Offer weekly follow-up calls for one month.~* Social Determinants of Health (SDoH) assessment.
Study NCT05765903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: * Diagnosis education.~* Follow-appointment scheduling assistance.~* Offer resources in the community.~* Offer weekly follow-up calls for one month.~* Social Determinants of Health (SDoH) assessment.
Study NCT05765903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Care
Description: * Additional educational training using computer tablet devices, such as iPads.~* Focus on readmission risk.~* Set-up Home Health Services (HHS), Mobile Integrated Healthcare (MIH) or Resources, Education and Access to Community Health (REACH).
Study NCT05708742 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Ultrasound
Description: A linear US transducer (Phillips-Saronno Italy) was placed vertically 3 cm lateral to the midline to visualize back muscles: the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, as well as the TPs with shimmering pleura in between.
Study NCT05708742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: A linear US transducer (Phillips-Saronno Italy) was placed vertically 3 cm lateral to the midline to visualize back muscles: the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, as well as the TPs with shimmering pleura in between.
Study NCT05708742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: The ESP block group underwent US-guided ESP block at L4 vertebrae level with 20 ml of bupivacaine 0.25%.
Study NCT05708742 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: saline solution
Description: The control group underwent the same procedure but had a sham injection (20 ml of saline).
Study NCT05708742 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Needle
Description: A 22-gauge short bevel needle (Spinocan, B. Braun Melsungen AG, Germany) was inserted in the cranial-caudal direction towards the TP in-plane with the US transducer until the needle touched the TP crossing all three muscles.
Study NCT05708742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle
Description: A 22-gauge short bevel needle (Spinocan, B. Braun Melsungen AG, Germany) was inserted in the cranial-caudal direction towards the TP in-plane with the US transducer until the needle touched the TP crossing all three muscles.
Study NCT06540950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: Vinorelbine is administered orally at 60mg per square meter per week by body surface area before radiotherapy and continued to be administered at 30mg per square meter per week during radiotherapy until the end of radiotherapy. Within 6 weeks after the end of radiotherapy, there are no serious side effects, and immune checkpoint inhibitors monotherapy can be performed.
Study NCT05801237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PE0116&PE0105
Description: This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients with Advanced Solid Tumor
Study NCT06526936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Information about diabetic foot care
Study NCT05504200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bladder and Pelvic Floor Muscle Training
Description: The intervention group will receive 8-weeks of at home PFMT, this will include 3 face-to-face visits, daily text reminders, and a weekly phone call.
Study NCT05521737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Intervention consists of a total of 32 sessions, divided into two intervention cycles, that is, 16 sessions over two months, with a rest period of one month in between. EA is applied for 20 minutes at an alternating frequency of 2 Hz. Acupunctural points are Zusanli (E36), Fenlong (E40), Yinlingquan (B9), Sanyinjiao (B6), Taichong (H3) and Zulinqi (VB41).
Study NCT05521737 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Intervention consists of a total of 32 sessions, divided into two intervention cycles, that is, 16 sessions over two months, with a rest period of one month in between. Sham acupuncture will be applied using a nonpuncture device without electrical stimulation at the same acupunctural points as in the EA group.
Study NCT06054217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle of TP-03
Description: The Exploratory Vehicle is the vehicle of TP-03 (lotilaner ophthalmic solution, 0.25%)
Study NCT06217120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine 0.5 mg daily
Study NCT06217120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study NCT06549751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT-601
Description: Cellular Therapy
Study NCT06547970 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Educational intervension
Description: an educational intervention about the disease, symptoms \& how to deal with these symptoms, foot care, life style like sport and nutritional advices
Study NCT06547970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervension
Description: an educational intervention about the disease, symptoms \& how to deal with these symptoms, foot care, life style like sport and nutritional advices
Study NCT05120739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% CHX cloths
Description: skin preparation in 2% CHX cloths
Study NCT05738681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N acetyl cysteine
Description: N acetyl cysteine 1,200 mg/day for 8 weeks in NAC group
Study NCT06405945 — intervention group
Intervention type: GENETIC
Intervention: PCR and sequence
Description: sequence the mutatation SNPs
Study NCT04871503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-899 Buttocks
Description: The treatment administration phase in both study groups will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899 will be applied over the gluteal area.
Study NCT06070948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral; Tablet
Study NCT05074758 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: alveolar dead-space quantification
Description: measurement of alveolar dead-space based on volumetric capnography
Study NCT05074758 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coagulation activation and impaired fibrinolysis explorations
Description: blood sampling:~* Fibrinolytic components~* NETs components~* Elastase-derived fragments of proteins of interest
Study NCT05074758 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endothelial activation / endothelial senescence
Description: circulating endothelial cells, E-selectin, endoglin, LVEF-A, LVEFR-2, Angiopoietin -1 and -2, cKit and SDF-1 Willebrand factor (activity, antigen, multimeric analysis )
Study NCT04982081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hiPSC-CM therapy
Description: 20 patients with congestive heart failure who met the inclusion and exclusion criteria will be recruited. After being fully informed and signed the informed consent, the patients will be randomly divided into two dosage groups: 100 million cells (10 patients) and 400 million cells (10 patients). Human iPSC-derived cardiomyocytes will be injected into the myocardium through a transcatheter endocardial injection system.
Study NCT06547983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized nutritional advice
Description: Participants in the intervention group received personalized nutrition advice based on their dietary habits, weight, anthropometric data and physical activity.
Study NCT06547983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized nutritional advice and food boxes
Description: Participants in the intervention plus group received the personalized nutrition advice while also receiving food boxes which are composed based on the personalized nutritional advice.
Study NCT05859386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness maintenance program
Description: 1. Four-week course to strengthen and extend skills learned in 8-week MBCT course. This will consist of four 2-hour sessions, occurring weekly for four weeks.~2. Monthly 1.5 hour meeting sessions. These will be led by an experienced MBCT teacher and will consist of a group meditation practice, a check-in time, and discussion of a topic relevant to the MBSR course.~3. Monthly check-in survey. This will be a brief (5 - 10 minute) survey (using Qualtrics) with questions about mood (PROMIS Depression and Positive Affect scales) and recent meditation practice.
Study NCT05406791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIRA App
Description: Support from coach and using the VIRA app
Study NCT05406791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mood Education App
Description: Support from mood education app
Study NCT06001034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusion training
Description: Impact of supervised occlusive training for 2 days per week for 10 weeks on quality of life and functional autonomy in participants with fibromyalgia.
Study NCT04822545 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: referral to comprehensive weight management clinic
Description: Patients will receive a referral for outpatient CWM clinic, with a message sent to the CWM clinic scheduler, prior to hospital discharge.~At six months after discharge, the patient will receive a phone call from the investigators to ascertain whether they were able to go to the CWM clinic and about their experience.
Study NCT06286865 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Easy-ICD
Description: Easy-ICD is an AI-based computer-assisted clinical coding (CAC) system that helps clinical coder assign ICD-10 codes to clinical notes such as discharge summaries.
Study NCT05152225 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI
Description: Brain MRI performed routinely in patients with EI
Study NCT05152225 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: digital subtraction angiography (DSA)
Description: Digital Subtraction Angiography (DSA) performed routinely in patients with EI
Study NCT05357378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hip Innovation Technology Reverse Hip Replacement System
Description: Implantation of the Investigational Device is performed using standard surgical procedures for THA, as described in the Instructions for Use (IFU). The control hip systems will be implanted in accordance with their respective IFU, which are also in line with standard surgical approaches for THA.